Related to BARDA Contracts Tetraphase for Antibiotic Development with $11.5M Up Front

• Tetraphase Pockets $45M to Progress Next-Generation Tetracyclines
  
• Tekmira Wins $34.7M Award to Develop RNAi Therapeutic against Ebola Virus
  
• Pfenex Scores Government Contract to Develop Production Process for Bulk Recombinant Protective Antigen from Anthrax
  
• Medicago Wins $21M DARPA Award to Scale Up Production of Flu Vaccines
  
• $6.3M DARPA Grant Allows GE to Assemble Team to Advance Nanosensor Technology
  
• Achaogen Wins $64M BARDA Contract to Develop Antibiotic for Biothreats
  
• Cellerant Scores $153M Contract for Acute Radiation Syndrome Treatment
  
• IntegenX Wins DTRA Contract to Develop Pathogen Detection and Identification Platform
  
• Pulmatrix Gets $5.7M DARPA Funding To Develop Host-Targeted Inhaled Therapies
  
• U.S. Army Awards $45.5M Contract to PPD for Clinical Trial Management
  
• DoD Pledges $4.6M to Establish Infection Genomics Center at UTSA
  
• Avaxia Gets Two-Year $2.9M Biodefense Award from BARDA
  
• Eureka Wins $750K SBIR Grant to Develop Technology for Detecting Anthrax Variants
  
• Rhenovia and French Army Awarded €1.15M to Develop Neurotoxin Biosimulation Platform
  
• BARDA to Give Neumedicines $17M to Progress Radiation Countermeasure
  
• BARDA Provides $56.3M to Support Five Drugs Against Radiation Injury
  
• Nanotherapeutics Wins $4.8M Contract for Oral Chelating Agent against Radiation Exposure
  
• Emergent Wins Potentially $1.25M Anthrax Vaccine Supply Contract
  
• Ablitech Gets $2M DoD Grant for R&D into Heterotopic Ossification
  
• CureVac, Sanofi Pasteur, and In-Cell-Art Collaborate on €33.1M DARPA-Supported Vaccine Program